News

Venaxis to Provide Business Update

Venaxis® announced that the Company will host an investor conference call to discuss FDA updates, European commercial activities, product development and other corporate matters. The April 7, 2015, 4:30 p.m. ET, conference call will be hosted by Steve Lundy, President and CEO.  Read more…



Venaxis Business Update

Venaxis announced that the Company will host an investor conference call to discuss business matters, including the recent FDA “Not Substantially Equivalent” response, on February 13, 2015, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, President and CEO.  Read more…



Venaxis Receives FDA “Not Substantially Equivalent” Response on APPY1 510(k) Submission

Venaxis, Inc. today announced the United States Food and Drug Administration (“FDA”) has determined that the APPY1 Test does not meet the criteria for substantial equivalence based upon data and information submitted by Venaxis in its 510(k) submission.  Read more…